The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Advances clinical research capabilities with leading regulatory grade registries platform
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Cipla has a robust governance model focused on sustainability
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Subscribe To Our Newsletter & Stay Updated
